Skip to main content
TipRanks
Go Ultimate75% OFF

Zota Health Care Ltd. (ZOTA) AI Stock Analysis

0 Followers
IN:ZOTA

Zota Health Care Ltd.

(NSE:ZOTA)

Select Model
Rating:47Neutral
Price Target:INR 1,199.00â–¼(-7.10% Downside)
Action:reiterated
Date:11/03/26

Financial performance is the primary driver, reflecting strong revenue growth but persistent losses and cash burn; technical indicators offer modest support while valuation is constrained by negative earnings.

Positive Factors
Strong Revenue GrowthRapidly accelerating revenue indicates expanding sales activity and stronger market reach across the company’s pharmaceutical portfolio. If Zota can retain customers and improve economics, this growing base could support operating leverage, broader distribution, and stronger earnings capacity over the next several quarters.
Negative Factors
Severe Margin CompressionThe sharp deterioration in gross and net margins shows that revenue growth is not translating into economically attractive sales. Continued pricing pressure, mix changes, or cost inflation could limit operating leverage and require a substantial improvement in product economics before earnings recover.

Zota Health Care Ltd. (ZOTA) vs. iShares MSCI India ETF (INDA)

-40%-30%-20%-10%0%10%IN:ZOTA-22.64%INDA-5.34%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 39.48B
Dividend Yield
0.08%
Average Volume (3M)
91.01K
Price to Earnings (P/E)
-38.5
Beta (1Y)
0.91
Revenue Growth
68.95%
EPS Growth
-55.82%
Country
India
Employees
635
Sector
General
Sector Strength
55
Industry
Biotechnology

Zota Health Care Ltd. Business Overview & Revenue Model

Company Description

Zota Health Care Limited is an Indian pharmaceutical firm dedicated to the development, manufacturing, and distribution of a broad spectrum of health-related products across India. Its extensive portfolio encompasses generic medications, over-the-cou...

How the Company Makes Money

Zota Health Care Ltd. makes money primarily by selling pharmaceutical and healthcare products, with revenue recognized from the sale of finished formulations marketed under its brands and supplied through its distribution network. Key revenue streams...

Zota Health Care Ltd. Financial Statement Overview

Summary

Strong revenue growth trajectory and stable balance sheet with manageable debt levels, though challenged by negative profitability and cash burn.

Income Statement

45Neutral

Balance Sheet

65Positive

Cash Flow

35Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue6.79B5.39B2.93B1.80B1.40B1.31B
Gross Profit733.05M639.06M1.56B803.38M310.68M418.86M
EBITDA14.42M185.40M-36.65M81.21M98.05M164.26M
Net Income-1.13B-739.36M-563.98M-143.48M-57.73M89.08M
Balance Sheet
Total Assets10.94B11.31B4.39B2.28B1.58B1.39B
Cash, Cash Equivalents and Short-Term Investments775.50M955.74M36.19M10.05M11.15M22.99M
Total Debt2.71B2.70B1.40B952.85M451.22M149.00M
Total Liabilities4.66B4.35B2.12B1.38B777.55M494.67M
Stockholders Equity6.26B6.93B2.24B899.77M803.57M896.27M
Cash Flow
Free Cash Flow0-1.92B-959.42M-226.94M-145.05M100.84M
Operating Cash Flow0-790.12M-499.64M-59.84M-20.06M133.32M
Investing Cash Flow0-3.22B-956.20M-129.03M147.03M-266.52M
Financing Cash Flow04.93B1.47B187.76M-138.81M142.73M

Zota Health Care Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price1290.60

Price Trends

50DMA1258.87Positive
100DMA1260.64Positive
200DMA1249.30Positive

Market Momentum

MACD3.60Negative
RSI51.79Neutral
STOCH61.36Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ZOTA, the sentiment is Positive. The current price of 1290.60 is above the 20-day moving average (MA) of 1273.81, above the 50-day MA of 1258.87, and above the 200-day MA of 1249.30, indicating a bullish trend. The MACD of 3.60 indicates Negative momentum. The RSI at 51.79 is Neutral, neither overbought nor oversold. The STOCH value of 61.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ZOTA.

Zota Health Care Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:ZOTA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:SUPRIYAIN:SUPRIYA69NeutralINR 49.93B28.20―0.16%23.00%-2.84%
IN:CONCORDBIOIN:CONCORDBIO57NeutralINR 116.17B41.14―1.36%4.02%-12.81%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:ONESOURCEIN:ONESOURCE48NeutralINR 181.34B-10538.67――10.66%-104.59%
IN:ZOTAIN:ZOTA47NeutralINR 39.15B-38.48―0.08%68.95%-55.82%
IN:PANACEABIOIN:PANACEABIO47NeutralINR 21.68B-304.05――19.43%―
IN:DCALIN:DCAL43NeutralINR 20.40B29.96――-20.86%-34.51%

* General Sector Average

Performance Comparison

-25%0%25%50%IN:ZOTAIN:CONCORDBIOIN:DCALIN:PANACEABIOIN:SUPRIYAIN:ONESOURCEDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:ZOTA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:ZOTAZota Health Care Ltd.1290.60-356.56-21.65%
IN:CONCORDBIOConcord Biotech Ltd.555.20-165.09-22.92%
IN:DCALDishman Carbogen Amcis Ltd.130.10-112.05-46.27%
IN:PANACEABIOPanacea Biotec Limited353.90-17.30-4.66%
IN:SUPRIYASupriya Lifescience Limited620.40-143.79-18.82%
IN:ONESOURCEOneSource Specialty Pharma Limited1581.35-124.50-7.30%

Zota Health Care Ltd. Corporate Events

Zota Health Care Submits Investor Presentation to NSE

Oct 28, 2026

Zota Health Care Limited has submitted an investor presentation to the National Stock Exchange of India in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The disclosure signals the company...

Zota Health Care Affirms No Deviation in QIP Proceeds Utilisation

Oct 28, 2026

Zota Health Care Limited reported to the National Stock Exchange that there was no deviation or variation in the use of proceeds from its Qualified Institutional Placement for the quarter ended September 30, 2026. The company raised Rs. 34,999.99 lak...

Zota Health Care Outlines Tax Treatment for Proposed Final Dividend

Sep 24, 2026

Zota Health Care Ltd. has informed shareholders that its board recommended a final dividend of 10%, equivalent to Re 1 per equity share of face value Rs 10, for the financial year 2025-26, subject to approval at the upcoming Annual General Meeting. T...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 03, 2026